In the years since hybridoma technology was invented, over 100 mAbs have entered the clinic and this class of drugs represents one of the fastest-growing areas of research and development. However, the production of hybridomas is ridden with potential bottlenecks and involves several steps, including the inoculation of mice with specific antigens, isolation of antibody-secreting …